Citation Review Articles

In the evolving landscape of cancer immunotherapy, the Major Histocompatibility Complex class I-related chain A and B (MICA/B) proteins have emerged as compelling targets. While their expression is induced by cellular stress, marking malignant cells for destruction by Natural Killer (NK) cells, tumors frequently evade this surveillance by proteolytically shedding MICA/B from their surface. This "molecular camouflage" not only reduces target density...

The landscape of biotherapeutic development is increasingly defined by the rigor of analytical comparability. In a recent study published in Biotechnology and Bioprocess Engineering, Lee et al. (2026) present a sophisticated MALDI-MS-based quantitative glycomics workflow that addresses long-standing challenges in N-glycan profiling. By utilizing ichorbio’s Etanercept Biosimilar...

The therapeutic landscape for breast cancer (BC) remains bifurcated by molecular subtypes. While triple-negative breast cancer (TNBC) has seen modest progress with immune checkpoint blockade (ICB), luminal (HR+) subtypes often present as "immunologically cold," characterized by low mutational...

Immune checkpoint blockade (ICB), particularly targeting the PD-1/PD-L1 axis, has redefined the treatment landscape for advanced gastric cancer (AGC). However, the clinical reality remains sobering: only approximately 15% of patients derive durable benefit from anti-PD-1 monotherapy. The majority of patients exhibit primary or adaptive...

The clinical history of CD137 (4-1BB) agonism is a tale of two extremes. On one side stands urelumab, an antibody with tremendous potency that failed due to severe, dose-limiting hepatotoxicity. On the other stands utomilumab, a molecule with...

The Genomic Stability-Immunity Axis

In the evolving landscape of cancer immunotherapy, the transition from "cold" to "hot" tumor microenvironments (TMEs) remains a primary therapeutic objective. A seminal paper recently published in...

For decades, the primary challenge in bone tissue engineering has been the "growth factor paradox." Standard in-vitro models typically rely on supraphysiological concentrations of recombinant proteins, such as RANKL and M-CSF...

The promise of CD70-targeted therapies...

Mechanistic insights supported by ichorbio’s in vivo PD-1 antibodies

A recent study utilizing the Bovine Viral Diarrhea Virus (BVDV) model has provided crucial insights into strategies for overcoming infection-induced...